William Blair analyst Andy Hsieh has reiterated their bullish stance on CRBP stock, giving a Buy rating on October 29.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andy Hsieh has given his Buy rating due to a combination of factors including Corbus Pharmaceuticals’ strong financial position and promising developments in their clinical pipeline. The company has extended its cash runway into 2028, supported by a substantial cash reserve of approximately $177.8 million, which provides a solid foundation for ongoing and future research initiatives.
Additionally, the promising data of CRB-701 in head and neck cancer presented at ESMO has set the stage for a pivotal trial initiation in mid-2026, reflecting potential future growth. The planned initiation of a Phase Ib study for CRB-913 in obesity and the upcoming announcement of Phase I data for CRB-601 further highlight the company’s active engagement in advancing its pipeline, which could lead to significant clinical and commercial success.
In another report released on October 29, Mizuho Securities also maintained a Buy rating on the stock with a $39.00 price target.